|
Manganese superoxide dismutase -102 genotype: overall and recurrence-free survivals |
||||
| Genotype |
Cases |
Deaths |
Hazard ratio minimally adjusteda (95% confidence interval) |
Hazard ratio fully adjustedb (95% confidence interval) |
|
|
||||
| Overall survival |
291 |
85 |
P for trend = 0.62 |
P for trend = 0.88 |
| CC |
180 |
55 |
1 (reference) |
1 (reference) |
| CT |
92 |
25 |
0.89 (0.55–1.43) |
0.75 (0.465–1.24) |
| TT |
19 |
5 |
0.88 (0.35–2.20) |
1.06 (0.42–2.69) |
| CC |
180 |
55 |
1 (reference) |
1 (reference) |
| CT + TT |
111 |
30 |
0.89 (0.57–1.38) |
0.80 (0.50–1.28) |
| Recurrence-free survival |
280c |
100 |
P for trend = 0.12 |
P for trend = 0.08 |
| CC |
175 |
68 |
1 (reference) |
1 (reference) |
| CT |
87 |
28 |
0.77 (0.50–1.20) |
0.65 (0.41–1.04) |
| TT |
18 |
4 |
0.55 (0.20–1.50) |
0.66 (0.24–1.83) |
| CC |
175 |
68 |
1 (reference) |
1 (reference) |
| CT + TT |
105 |
32 |
0.73 (0.48–1.12) |
0.65 (0.42–1.01) |
|
CC, homozygous for the wild-type manganese superoxide dismutase gene; CT, heterozygous for the variant genotype; TT, homozygous for the variant genotype. aMinimally adjusted model: age. bFully adjusted model: age, stage with node status at diagnosis, race, estrogen receptor status, and progesterone receptor status. cEleven subjects were never disease free, thus they were deleted for recurrence-free survival. | ||||
Martin et al. Breast Cancer Research 2006 8:R45 doi:10.1186/bcr1532 |
||||